Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)

NCT01538329 is registered in ClinicalTrials.gov with University Hospital, Toulouse as lead sponsor.

NCT NCT01538329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01538329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)
Lead sponsor
University Hospital, Toulouse
Phase
Phase 2
Overall status
Completed
Start date
March 4, 2012
Completion date
February 26, 2019
Enrollment
210 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease